US House of Reps narrowly passes $1,000 billion over 10 years health reform bill

9 November 2009

In an unusual Saturday sitting, the US Democratic-controlled House has narrowly - by a vote of 220 to 215 - passed landmark and far-reaching health care reform legislation - H.R. 3962 - designed to provide health insurance to an additional 36 million Americans at a cost of more than $1,000 billion over a decade, handing President Barack Obama a victory on his signature domestic priority. 'The House of Representatives passed a bill that would finally make real the promise of quality, affordable health care for the American people,' the President said in a statement after the vote, also urging the Senate to do likewise.

The bill was supported by 219 Democrats and one Republican - Joseph Cao from New Orleans - and opposed were 176 Republicans and 39 Democrats. The Bill passed after a last minute compromise on abortion funding and a scaling back of the public plan option. The debate now moves to the Senate, where Mr Obama is one short of the 60 votes needed, as two Senators oppose the public plan. Moreover, the abortion compromise has inflamed sensitivies in both the House and Senate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical